Ocugen completes $115 million convertible notes offering to extend runway

Go back to Ocugen completes $115 million convertible notes offering to extend runway

Ocugen Provides Business Update with First Quarter 2026 Financial Results

May 5, 2026 8:32 AM EDT

Conference Call and Webcast Today at 8:30 a.m. ET

Positive 12-month data from the OCU410 Phase 2 ArMaDa clinical trial for geographic atrophy (GA) indicates a statistically significant (p 30% reduction in Iesion growth compared to control, with a favorable safety and tolerability profileAllows robust registrational Phase 3 trial design, a potential combined U.S./EU trial with 300... More